Jaguar Health's Phase 3 OnTarget trial for crofelemer in breast cancer patients shows significant diarrhea prevention improvement.

Jaguar Health announced that its Phase 3 OnTarget trial for crofelemer, aimed at preventing diarrhea related to cancer therapy, showed significant improvement in breast cancer patients. The trial included nearly 180 breast cancer participants among 287 total. Findings have been submitted for presentation at an oncology conference and are anticipated to be published in a peer-reviewed journal. Crofelemer is derived from rainforest plants and treats gastrointestinal issues.

Articles

Street Insider

PR-inside

Tennessee Daily

Finanz Nachrichten

Toronto Telegraph

Salt Lake City Sun

-- show less --

Further Reading

Related Stories